FINWIRES · TerminalLIVE
FINWIRES

Australian Federal Court Partially Dismisses Proceeding Brought by Former Coles Group Unit Employee Over Dismissal

By

The Federal Court of Australia partially dismissed proceeding brought by Sahil Verma, a former employee of Coles Group's (ASX:COL) Coles Supermarkets Australia, alleging racial and disability discrimination as well as breaches of the Fair Work Act, noting that they have no reasonable prospects of success, according to a court document on Monday.

Verma was employed by Coles Australia as a casual trolley collector from Nov. 22, 2021, until Feb. 9, 2024, when his employment was terminated. He alleged that an employee of Coles made racial comments toward him. The Fair Work Commission (FWC) dismissed Verma's application, finding that it had been made outside the 21 days after the date on which the dismissal took effect, contrary to legal requirements.

Coles had submitted that Verma's claim was incompetent because the FWC had not issued a certificate in relation to the dispute before he applied to the court. Verma did not dispute that he had no such certificate.

The court said that since Verma could not satisfy the legal requirements, the court did not have jurisdiction to entertain his claims.

Verma had also lodged a complaint to the Australian Human Rights Commission (AHRC) on Nov. 10, 2024, alleging that he had been discriminated against because of his disability, a mental illness, and his race.

Coles Group's shares fell nearly 1% in recent trading on Monday.

Related Articles

Asia

Genrix Grants CQ Pharmaceutical Distribution Rights for Myeloma Drug in China, Hong Kong, Macau, Taiwan

Chongqing Genrix Biopharmaceutical (SHA:688443) granted C.Q. Pharmaceutical (SHE:000950) subsidiary Yaoyou Pharmaceutical exclusive development and distribution rights for the GR1803 drug across China and Hong Kong, Macau, and Taiwan.The agreement covers development such as clinical trials, research, and manufacturing, as well as sales, the filing said.The GR1803 velitumimumab drug is indicated for multiple myeloma, a rare form of blood cancer.Yaoyou will pay Genrix up to 600 million yuan in initial payment, listing milestone, and technology transfer milestone payments.Genrix will also be eligible to receive sales royalties of up to a minimum percentage of two digits.

SHA:688443SHE:000950
Asia

Xuan Wu Cloud's CFO Steps Down

Xuan Wu Cloud Technology's (HKG:2392) Chief Financial Officer Ge Ping resigned to devote more time to personal affairs effective May 31, according to a Friday Hong Kong bourse filing.

HKG:2392
Asia

Update: Xi'an Eswin Materials Technology to Invest Up to 40 Million Yuan in Glassmaker's Funding Round

Xi'an Eswin Materials Technology (SHA:688783) will invest up to 40 million yuan in a pre-A+ funding round for Zhuhai Yiyuan Technology, according to a Friday filing with the Shanghai bourse.Zhuhai Yiyuan Technology seeks to raise between 100 million yuan and 200 million yuan in a funding round.The glass manufacturer plans to use the proceeds for capacity expansion, equipment procurement, and technology upgrades.

SHA:688783